{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Insulin+Treated+Type+2+Diabetes+Mellitus",
    "query": {
      "condition": "Insulin Treated Type 2 Diabetes Mellitus"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 166,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Insulin+Treated+Type+2+Diabetes+Mellitus&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T03:22:33.641Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03434119",
      "title": "Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/Lixisenatide",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine (HOE901)",
          "type": "DRUG"
        },
        {
          "name": "Background therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2018-02-20",
      "completion_date": "2019-01-07",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 85,
      "location_summary": "Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03434119"
    },
    {
      "nct_id": "NCT03922750",
      "title": "A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin icodec",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine U100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 154,
      "start_date": "2019-05-09",
      "completion_date": "2020-01-27",
      "has_results": true,
      "last_update_posted_date": "2022-01-18",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 13,
      "location_summary": "Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Nashua",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03922750"
    },
    {
      "nct_id": "NCT05352815",
      "title": "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "IcoSema",
          "type": "DRUG"
        },
        {
          "name": "Insulin icodec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1291,
      "start_date": "2022-06-01",
      "completion_date": "2024-04-23",
      "has_results": true,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 110,
      "location_summary": "Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 90 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05352815"
    },
    {
      "nct_id": "NCT02033499",
      "title": "Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)"
      ],
      "interventions": [
        {
          "name": "SMBG",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "30 Years to 99 Years"
      },
      "enrollment_count": 450,
      "start_date": "2014-01",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-12-14",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02033499"
    },
    {
      "nct_id": "NCT01774968",
      "title": "Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Human Regular U-500 Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 325,
      "start_date": "2013-02",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2015-09-22",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 35,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01774968"
    },
    {
      "nct_id": "NCT02060916",
      "title": "Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Treated With Insulin"
      ],
      "interventions": [
        {
          "name": "PAZ320",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-03",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 1,
      "location_summary": "Jefferson, New Hampshire",
      "locations": [
        {
          "city": "Jefferson",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02060916"
    },
    {
      "nct_id": "NCT00982644",
      "title": "Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1030,
      "start_date": "2009-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-09",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 86,
      "location_summary": "Bay Minette, Alabama • Birmingham, Alabama • Huntsville, Alabama + 80 more",
      "locations": [
        {
          "city": "Bay Minette",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00982644"
    },
    {
      "nct_id": "NCT00309244",
      "title": "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Technosphere® Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 677,
      "start_date": "2006-02",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-10-16",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 80,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309244"
    },
    {
      "nct_id": "NCT05462756",
      "title": "A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Type 2 Diabetes Treated With Insulin"
      ],
      "interventions": [
        {
          "name": "Insulin Efsitora Alfa",
          "type": "DRUG"
        },
        {
          "name": "Insulin Lispro (U100)",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine (U100)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 730,
      "start_date": "2022-08-11",
      "completion_date": "2024-02-27",
      "has_results": true,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 24,
      "location_summary": "Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more",
      "locations": [
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Blackfoot",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05462756"
    },
    {
      "nct_id": "NCT00768105",
      "title": "To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "AZD1656",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-09",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2010-12-03",
      "last_synced_at": "2026-10-01T03:22:33.641Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00768105"
    }
  ]
}